Beijing Enterprises Holdings signed a new three-year Financial Services Agreement with the finance company on July 14, effective from August 28, 2026 to August 27, 2029, with an annual cap of RMB12.5 billion for deposit services. The agreement constitutes a continuing connected transaction and major transaction, requiring an EGM for independent shareholders' approval, with Beijing Enterprises Group and its close associates abstaining from voting. Loan services and other financial services are fully exempt.
Juhe Data's wholly-owned subsidiary Juhe Tianqing signed an EPC contract on July 14 with the contractor to build the Public Security Large Model and Report Robot Production Headquarters in Suzhou for approximately RMB101.87 million (tax-inclusive), with a total construction area of approximately 28,351.3 square meters, an expected construction period of 460 days, and a planned completion date of October 28, 2027. The transaction constitutes a discloseable transaction exempt from shareholders' approval.
SF Intra-city announced on July 14 that its controlling shareholder SF Tyson plans to convert approximately 171.76 million domestic shares (representing 18.72% of issued share capital) into H-shares. The Company has submitted an application to the CSRC, but the filing procedures are not yet completed and implementation plan details remain undetermined. SF Tyson and SF Holding currently have no reduction plans.
WEICHAI POWER(02338.HK) will spend CNY 107.3 million to repurchase 21.92 million shares on Jul 14, 2026 .
NewTimeSpace News: Estun announced on 14 July that it expects net profit attributable to parent shareholders for the first half of 2026 to range from RMB 150 million to RMB 180 million, representing a year-on-year increase of 2,144.74% to 2,593.68%.
NewTimeSpace News: CHINA DEVELOPMENT BANK FINANCIAL LEASINGannounced on 14 July that three wholly-owned subsidiaries of the Company entered into shipbuilding contract assignment agreements with the original buyer and the seller to acquire three multi-purpose bulk carriers, with a total consideration capped at USD 138 million.
NewTimeSpace News: Holly Futuresannounced on 14 July that Mr. Zhang Hongfa, Independent Director of the Company, resigned from his posts as Independent Director of the 5th Board of Directors, Chairman of the Nomination Committee, and member of the Risk Management Committee, Remuneration Committee and Strategy & ESG Committee due to personal reasons.
NewTimeSpace News: Shenwan Hongyuan announced on 14 July that its subsidiary Shenwan Hongyuan Securities has received an official approval from the China Securities Regulatory Commission (CSRC), which greenlights its registration application for public offering of perpetual subordinated bonds to professional investors with an aggregate face value not exceeding RMB 30 billion.
NewTimeSpace News: Luxxu Groupannounced on 14 July that Mr. Yang Xi, Executive Director, has resigned from his positions as Executive Director, member of the Remuneration Committee and Authorised Representative due to personal career development and other official commitments, with effect from 14 July.
NewTimeSpace News: United Laboratories announced on 14 July that sodium hyaluronate eye drops (specification: 0.3%, 5ml:15mg) submitted by Zhongshan Branch of Zhuhai United Laboratories, its wholly-owned subsidiary, has passed the drug registration review and approval of the National Medical Products Administration and been granted marketing authorization.
NewTimeSpace News: Dongjiang Environmental announced on 14 July that it expects a net loss attributable to shareholders of the listed company of approximately RMB 250 million to RMB 270 million for the first half of 2026, representing a loss reduction of roughly 2.94% to 10.13% compared with the loss of RMB 278 million recorded in the same period last year.
NewTimeSpace News: CSPC Pharmaceutical Group announced on 14 July that its self-developed albumin-bound docetaxel for injection (HB1801) and Anitumab (KN026), a co-developed HER2 bispecific antibody, have been awarded breakthrough therapy designation by the National Medical Products Administration (NMPA).
NewTimeSpace News: China Everbright Water announced on 14 July that the Company has completed the issuance of Phase 1 medium-term notes for 2026 with an issuing principal of RMB 1.5 billion and a coupon rate of 1.80%.
NewTimeSpace News: MicroTech Medical announced on 14 July that its LinX continuous glucose monitoring system has recently obtained marketing approval in South Korea, indicated for continuous real-time glucose monitoring in adults.
NewTimeSpace News: Overseas Chinese Town Asia announced on 14 July that the public listing procedure for the proposed sale of 100% equity interest in OCT (Huizhou) has been completed. Hont Electronics (Huizhou) Co., Ltd. has been confirmed as the winning bidder with a final consideration of around RMB 307 million.
NewTimeSpace News: Sino Biopharmaceutical announced on 14 July that TRD205, a Class 1 new drug (AT2R antagonist) independently developed by its subsidiary Beijing Tide Pharmaceutical, has completed Phase II clinical trials for chronic postoperative neuropathic pain. Supported by positive trial data, the drug has been granted breakthrough therapy designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration.
